Neoplasms by Site Active Not Recruiting Phase 3 Trials for Savolitinib (DB12048)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.Treatment